<DOC>
	<DOCNO>NCT02853344</DOCNO>
	<brief_summary>The purpose study assess safety efficacy monotherapy pembrolizumab ( MK-3475 ) participants renal cell carcinoma ( RCC ) . There two cohort study : Cohort A consist participant clear cell ( cc ) RCC Cohort B consist participant non-clear cell ( ncc ) RCC .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Monotherapy Locally Advanced/Metastatic Renal Cell Carcinoma ( MK-3475-427/KEYNOTE-427 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Cohort A ( clear cell RCC cohort ) participant must histologically confirm diagnosis clear cell RCC RCC clear cell component ( without sarcomatoid feature ) . Cohort B ( nonclear cell RCC cohort ) participant must histologically confirm diagnosis nonclear cell RCC ( without sarcomatoid feature ) . Participants tumor component clear cell histology eligible inclusion Cohort B . Has locally advanced/metastatic disease , i.e. , Stage IV RCC per American Joint Committee Cancer ( AJCC ) recurrent disease . Has measurable disease per RECIST 1.1 assess BICR . Has receive prior systemic therapy advance RCC . Must provide adequate tissue biomarker analysis Cohorts A B archival tissue sample newly obtain core excisional biopsy tumor lesion previously irradiate . Participants receive bone resorptive therapy ( include limit bisphosphonate RANKL inhibitor ) must stable dos ≥4 week prior treatment allocation . Has Karnofsky Performance Status ( KPS ) ≥70 % , assess within 10 day prior treatment allocation . Demonstrates adequate organ function . Female participant childbearing potential must willing use adequate method contraception course study 120 day last dose study drug . Male participant childbearing potential must agree use adequate method contraception start first dose study drug 120 day last dose study drug . Is currently participate participate study investigational agent use investigational device within 4 week prior allocation , major surgery within 4 week prior allocation radiation therapy within 2 week prior allocation , recover ( i.e. , ≤ Grade 1 Baseline ) AEs due prior treatment . Had prior treatment antiprogrammed cell death 1 ( antiPD1 ) , antiprogrammed cell death ligand 1 ( PDL1 ) , PDL2 agent antibody target immuneregulatory receptor mechanisms . Examples antibody include antibody indoleamine2,3dioxygenase ( IDO ) , PDL1 , interleukin 2 receptor ( IL2R ) , glucocorticoidinduced tumor necrosis factor receptorrelated protein ( GITR ) . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study treatment , except case central nervous system ( CNS ) metastases ( see ) . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic immunosuppressive agent . Has know additional malignancy progression require active treatment last 3 year . Note : Participants basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy carcinoma situ exclude . Has know active CNS metastasis and/or carcinomatous meningitis . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Has active infection require systemic therapy . Has know history Human Immunodeficiency Virus ( HIV ) infection . Has know active Hepatitis B Hepatitis C. Has receive live virus vaccine within 30 day treatment allocation . Has prior solid organ transplant . Is pregnant breastfeeding , expect conceive father child within project duration study , start screen visit 120 day last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>